Just reported
From Exelixis's results release of 29 de octubre de 2026; its quarterly report has since been filed.
Actual
658,7M US$
+10 % y/y
+4,8 % q/q
Guided
—
No guide given
Actual
0,85 US$
+23 % y/y
+3,7 % q/q
Guided
—
No guide given
Actual
268,4M US$
+13 % y/y
+8,1 % q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Los porcentajes de ingresos son estimaciones para year ended 2025-12-31, no cifras de un informe oficial.
CABOMETYX (cabozantinib) tablets
A cancer medicine used alone for several cancers, including kidney, liver, thyroid and neuroendocrine cancers, and with nivolumab for some kidney cancers.
COMETRIQ (cabozantinib) capsules
A cabozantinib medicine for progressive, metastatic medullary thyroid cancer.
COTELLIC (cobimetinib)
A medicine used in combination treatments for certain forms of advanced melanoma; Genentech markets it under a collaboration with Exelixis.
MINNEBRO (esaxerenone)
A medicine for high blood pressure in Japan, licensed to Daiichi Sankyo.
Zanzalintinib
An experimental cancer medicine being tested alone and with other medicines. Exelixis has applied for U.S. approval of its use with atezolizumab for previously treated metastatic colorectal cancer.
XL309
An experimental medicine being tested in people with advanced solid tumors, alone and with a drug that blocks PARP, a protein involved in cell repair.
Estados financieros completos →
Exelixis’s main medicine is Cabometyx, a tablet used to treat several cancers, including kidney cancer; it is also used with Bristol Myers Squibb’s nivolumab for some patients. Exelixis sells Cabometyx and Cometriq in the United States, while Ipsen and Takeda sell cabozantinib in other countries and pay Exelixis royalties. The company also earns money from licensing and collaborating on other medicines, including Cotellic and Minnebro, and is developing cancer drug candidates such as zanzalintinib. The U.S. Food and Drug Administration is reviewing zanzalintinib with atezolizumab for previously treated colorectal cancer.
Construido a partir de los propios informes de Exelixis, Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
68,99 US$-1,2 %cierre 13 nov
Cifras hasta el 2 de octubre de 2026, del 10-Q presentado el 29 de octubre de 2026
Exelixis sells cancer medicines, chiefly Cabometyx, to U.S. wholesalers and specialty pharmacies, and earns royalties from partners selling cabozantinib abroad.
The themes Exelixis is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade A+
La franja bajo el precio muestra la calificación en cada fecha, calculada solo con los informes ya públicos en ese momento.
Mostrando 2 de 41 trimestres del historial de calificaciones de Exelixis, Inc.. Los otros 39 llegan hasta noviembre de 2016.
